Nome |
# |
Multitarget Drugs: Focus on the NO-donor hybrid drugs, file e27ce426-b4e8-2581-e053-d805fe0acbaa
|
333
|
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs, file e27ce426-d83a-2581-e053-d805fe0acbaa
|
253
|
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance., file e27ce426-e3dd-2581-e053-d805fe0acbaa
|
252
|
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity, file e27ce42c-26e7-2581-e053-d805fe0acbaa
|
246
|
New nitric oxide or hydrogen sulfide releasing aspirins, file e27ce426-d99c-2581-e053-d805fe0acbaa
|
245
|
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties, file e27ce426-aadd-2581-e053-d805fe0acbaa
|
229
|
Leishmanicidal Activity of Novel Synthetic Furoxan and Benzofuroxan Derivatives, file e27ce429-8b1b-2581-e053-d805fe0acbaa
|
229
|
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein, file e27ce426-c64d-2581-e053-d805fe0acbaa
|
196
|
Novel Antioxidant Agents Deriving From Molecular Combination of Vitamin C and NO-donor moieties, file e27ce426-aaa3-2581-e053-d805fe0acbaa
|
179
|
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties, file e27ce426-ae93-2581-e053-d805fe0acbaa
|
172
|
A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion, file e27ce427-0dd8-2581-e053-d805fe0acbaa
|
163
|
Doxorubicin-antioxidant multitarget drugs, file e27ce426-f93b-2581-e053-d805fe0acbaa
|
144
|
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance., file e27ce426-e3df-2581-e053-d805fe0acbaa
|
139
|
Edaravone derivatives containing NO-donor functions, file e27ce426-bc77-2581-e053-d805fe0acbaa
|
135
|
Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors, file e27ce429-3fcd-2581-e053-d805fe0acbaa
|
127
|
Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors, file e27ce42c-8704-2581-e053-d805fe0acbaa
|
126
|
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties, file e27ce426-ae92-2581-e053-d805fe0acbaa
|
111
|
Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis, file e27ce429-b98b-2581-e053-d805fe0acbaa
|
106
|
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins, file e27ce428-7e0a-2581-e053-d805fe0acbaa
|
96
|
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells, file e27ce426-f58a-2581-e053-d805fe0acbaa
|
94
|
Mitochondrial delivery of phenol substructure triggers mitochondrial depolarization and apoptosis of cancer cells, file e27ce42c-f044-2581-e053-d805fe0acbaa
|
94
|
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance, file e27ce428-be10-2581-e053-d805fe0acbaa
|
92
|
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins, file e27ce426-b275-2581-e053-d805fe0acbaa
|
90
|
New tetrahydroisoquinoline derivatives overcome pgp activity in brain-blood barrier and glioblastoma multiforme in vitro, file e27ce42c-d292-2581-e053-d805fe0acbaa
|
81
|
New nitric oxide or hydrogen sulfide releasing aspirins, file e27ce426-d99d-2581-e053-d805fe0acbaa
|
72
|
Doxorubicin-antioxidant multitarget drugs, file e27ce426-f93a-2581-e053-d805fe0acbaa
|
70
|
Effects of Nitric Oxide Donor Antioxidants Containing the Phenol Vitamin E Substructure and a Furoxan Moiety on Ischemia/Riperfusion Injury, file e27ce426-bc73-2581-e053-d805fe0acbaa
|
66
|
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease, file e27ce427-2d2f-2581-e053-d805fe0acbaa
|
66
|
Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants, file e27ce426-b11b-2581-e053-d805fe0acbaa
|
61
|
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance, file e27ce428-bf82-2581-e053-d805fe0acbaa
|
61
|
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein, file e27ce426-c64c-2581-e053-d805fe0acbaa
|
59
|
Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents, file e27ce426-ef96-2581-e053-d805fe0acbaa
|
57
|
NO-Donor Melatonin Derivatives: Synthesis And In Vitro Pharmacological Characterization, file e27ce426-bbd1-2581-e053-d805fe0acbaa
|
56
|
Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile, file e27ce426-baef-2581-e053-d805fe0acbaa
|
50
|
Edaravone derivatives containing NO-donor functions, file e27ce426-bc79-2581-e053-d805fe0acbaa
|
50
|
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity, file e27ce426-c49d-2581-e053-d805fe0acbaa
|
50
|
Low concentrations of an nitric oxide-donor combined with a liposoluble antioxidant compound enhance protection against reperfusion injury in isolated rat hearts, file e27ce426-be73-2581-e053-d805fe0acbaa
|
49
|
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations, file e27ce42c-fa2a-2581-e053-d805fe0acbaa
|
48
|
Direct introduction of cyano group on furoxan ring, file e27ce42c-6ab8-2581-e053-d805fe0acbaa
|
44
|
Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis, file e27ce42f-1217-2581-e053-d805fe0acbaa
|
44
|
Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation, file e27ce42d-c537-2581-e053-d805fe0acbaa
|
41
|
Multitarget antioxidant NO-donor organic nitrates: a novel ap-proach to overcome nitrates tolerance, an ex vivo study, file e27ce434-a776-2581-e053-d805fe0acbaa
|
41
|
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma, file e27ce432-dd86-2581-e053-d805fe0acbaa
|
40
|
Multitarget Drugs: No-Donor Doxorubicins, file e27ce427-664a-2581-e053-d805fe0acbaa
|
36
|
New furoxan derivatives for the treatment of ocular hypertension, file e27ce42b-615d-2581-e053-d805fe0acbaa
|
36
|
Direct introduction of cyano group on furoxan ring, file e27ce42c-3791-2581-e053-d805fe0acbaa
|
34
|
Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies, file e27ce42c-91c9-2581-e053-d805fe0acbaa
|
34
|
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts, file e27ce42e-af48-2581-e053-d805fe0acbaa
|
34
|
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors, file e27ce435-6c36-2581-e053-d805fe0acbaa
|
34
|
New furoxan derivatives for the treatment of ocular hypertension, file e27ce42b-15a7-2581-e053-d805fe0acbaa
|
32
|
New tetrahydroisoquinoline-based P-glycoprotein modulators: Decoration of the biphenyl core gives selective ligands, file e27ce42d-8df5-2581-e053-d805fe0acbaa
|
32
|
Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug, file e27ce435-98a8-2581-e053-d805fe0acbaa
|
29
|
Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4′-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein, file e27ce42a-1188-2581-e053-d805fe0acbaa
|
28
|
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance, file e27ce42b-3a6a-2581-e053-d805fe0acbaa
|
28
|
Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile, file e27ce426-baf0-2581-e053-d805fe0acbaa
|
26
|
Screening for potential hazard effects from a multitarget anthracycline on the cardiovascular system, file e27ce427-a562-2581-e053-d805fe0acbaa
|
26
|
gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension, file e27ce42c-8ff0-2581-e053-d805fe0acbaa
|
25
|
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance, file e27ce42b-59af-2581-e053-d805fe0acbaa
|
23
|
Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis, file e27ce429-f403-2581-e053-d805fe0acbaa
|
22
|
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors, file e27ce433-469a-2581-e053-d805fe0acbaa
|
22
|
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity, file e27ce426-c49c-2581-e053-d805fe0acbaa
|
21
|
Multitarget Drugs: No-Donor Doxorubicins, file e27ce427-664b-2581-e053-d805fe0acbaa
|
21
|
MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE, file e27ce429-dd38-2581-e053-d805fe0acbaa
|
21
|
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors, file e27ce42c-ef0f-2581-e053-d805fe0acbaa
|
20
|
Planning, synthesis and anti-Mycobacterium tuberculosis activity of N-oxide derivatives, file e27ce42e-d34d-2581-e053-d805fe0acbaa
|
18
|
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins, file e27ce426-b276-2581-e053-d805fe0acbaa
|
16
|
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease, file e27ce427-2d32-2581-e053-d805fe0acbaa
|
15
|
Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors, file e27ce429-459c-2581-e053-d805fe0acbaa
|
15
|
Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment:
Preliminary Studies on Cultured Cells, file e27ce42b-0927-2581-e053-d805fe0acbaa
|
15
|
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma, file e27ce42e-1c89-2581-e053-d805fe0acbaa
|
15
|
INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER, file e27ce42e-7875-2581-e053-d805fe0acbaa
|
15
|
IN VITRO CARDIOVASCULAR TOXICITY RISK ASSESSMENT OF NOVEL H2S-DONATING ANTHRACYCLINE, file e27ce42c-332e-2581-e053-d805fe0acbaa
|
14
|
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells, file e27ce431-9d9c-2581-e053-d805fe0acbaa
|
14
|
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs, file e27ce426-d83b-2581-e053-d805fe0acbaa
|
13
|
Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies, file e27ce42a-2c87-2581-e053-d805fe0acbaa
|
13
|
Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug, file e27ce42e-df97-2581-e053-d805fe0acbaa
|
12
|
Naked and Decorated Nanoparticles Containing H2S-Releasing Doxorubicin: Preparation, Characterization and Assessment of Their Antitumoral Efficiency on Various Resistant Tumor Cells, file 01a17931-38bf-4387-8a34-bfc4367cc146
|
8
|
N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation, file e260b6d2-2b05-4664-b2f5-644d7b2e365f
|
8
|
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins, file e27ce428-7f7e-2581-e053-d805fe0acbaa
|
7
|
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors, file e27ce42c-a984-2581-e053-d805fe0acbaa
|
7
|
Use of Enzymatically Activated Carbon Monoxide Donors for Sensitizing Drug-Resistant Tumor Cells, file 3576b7e4-3057-45d2-bb29-862a088242ed
|
6
|
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance, file e27ce42b-2369-2581-e053-d805fe0acbaa
|
6
|
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells, file e27ce431-259d-2581-e053-d805fe0acbaa
|
6
|
Comparative Study of Different H2S Donors as Vasodilators and Attenuators of Superoxide-Induced Endothelial Damage, file e80b50e2-8b98-45e7-9ee5-3d72ab9566e8
|
6
|
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma, file e27ce42e-0506-2581-e053-d805fe0acbaa
|
5
|
Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis, file e27ce42c-84fa-2581-e053-d805fe0acbaa
|
4
|
New tetrahydroisoquinoline-based P-glycoprotein modulators: Decoration of the biphenyl core gives selective ligands, file e27ce42c-f046-2581-e053-d805fe0acbaa
|
4
|
Multitarget antioxidant NO-donor organic nitrates: a novel approach to overcome nitrates tolerance, file 8a501c96-7179-442f-96a3-526d0ba798a8
|
3
|
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins, file e27ce426-b5e2-2581-e053-d805fe0acbaa
|
3
|
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance., file e27ce426-e3e0-2581-e053-d805fe0acbaa
|
3
|
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells, file e27ce426-f589-2581-e053-d805fe0acbaa
|
3
|
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease, file e27ce427-3667-2581-e053-d805fe0acbaa
|
3
|
New furoxan derivatives for the treatment of ocular hypertension, file e27ce42b-615c-2581-e053-d805fe0acbaa
|
3
|
Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis, file e27ce42c-b575-2581-e053-d805fe0acbaa
|
3
|
New lipophilic organic nitrates: Candidates for chronic skin disease therapy, file ddc0baf1-1e37-458b-8507-13ee2406149a
|
2
|
Unsymmetrically Substituted Furoxans. Part 19. Methyl and Phenylfuroxansulfonic Acids and Related Sulfonamides, file e27ce426-b5e7-2581-e053-d805fe0acbaa
|
2
|
Doxorubicin-antioxidant multitarget drugs, file e27ce426-f93c-2581-e053-d805fe0acbaa
|
2
|
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance, file e27ce428-bf7d-2581-e053-d805fe0acbaa
|
2
|
gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension, file e27ce42c-3c79-2581-e053-d805fe0acbaa
|
2
|
Aceclofenac-galactose conjugate: design, synthesis, characterization and pharmacological and toxicological evaluations, file e27ce42d-8dfb-2581-e053-d805fe0acbaa
|
2
|
Totale |
5.816 |